Tolerability and Adverse Events of Adjuvant Chemotherapy for Rectal Cancer in Patients With Diverting Ileostomy

Conclusion: Completion rate of ACT in patients with diverting ileostomy was lower than that of colorectal cancer patients in the previous studies. UFT/LV may be a more tolerable regimen than Capecitabine or CAPOX in colorectal cancer patients with diverting ileostomy.

Source: In Vivo - November 3, 2020 Category: Research Authors: TAKAHASHI, J., TSUJINAKA, S., MAEMOTO, R., MIYAKURA, Y., SUZUKI, K., FUKUDA, R., SAKIO, R., MACHIDA, E., RIKIYAMA, T. Tags: Clinical Studies Source Type: research